Targeting the molecular target of rapamycin (mTOR)

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 564-575

  Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

AP25373; CCI 779; Molecular target of rapamycin; Phosphatase and tensin homologue deleted on chromosome 10; RAD001; Rapamycin

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON A; AP 23573; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FK 506 BINDING PROTEIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; INTERLEUKIN 2; LETROZOLE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; TUBERIN; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BIPOLAR DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER; CANCER INHIBITION; CELL PROLIFERATION; CHROMOSOME 10; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; DRY SKIN; ECZEMA; FOLLICULITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MESOTHELIOMA; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN DEFECT; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TUBEROUS SCLEROSIS;

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; PROTEIN KINASES; SIROLIMUS;

EID: 8344281974     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000143964.74936.d1     Document Type: Review

References (105)

1. Jacinto E, Hall MN: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4:117-126. The conservation of TOR signaling from yeast to mammals is reviewed, and the role of mTOR in controlling growth and sensing nutrients and growth factors is discussed.
2. Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15:807-826.
3. Schmeizie T, Hall MN: TOR, a central controller of cell growth. Cell 2000, 103:253-262.
4. Fingar DC, Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
5. Edinger AL, Linardic CM, Chiang GG, et al.: Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 2003, 63:8451-8460.
6. Hoye A, Tanabe K, Lemos PA, et al.: Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 2004, 43:1954-1958.
7. Moses JW, Leon MB, Popma JJ, et al.: SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
8. Marks AR: Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 2003, 349:1307-1309. Commentary on the use of sirolimus-eluting cardiac arterial stents in preventing restenosis and associated clinical events in all subgroups analyzed.
9. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348. Excellent review of the role of mTOR-related pathways that also discusses molecular aberrations of pathway elements and rapamycin sensitivity.
10. Mita MM, Mita A, Rowinsky EK: Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003, 4:126-137. Reviews preclinical rationale and early clinical trial results with inhibitors of mTOR with a particular slant toward breast cancer therapeutics.
11. Brown EJ, Albers MW, Shin TB, et al.: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
12. Kunz J, Henriquez R, Schneider U, et al.: Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993, 73:585-596.
13. Fang Y, Vilella-Bach M, Bachmann R, et al.: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001, 294:1942-1945.
14. Dennis PB, Jaeschke A, Saitoh M, et al.: Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294:1102-1105.
15. Suh JM, Song JH, Kim DW, et al.: Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. J Biol Chem 2003, 278:21960-21971.
16. Proud CG: Regulation of mammalian translation factors by nutrients. Eur J Biochem 2002, 269:5338-5349.
17. Kim DH, Sarbassov DD, Ali SM, et al.: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
18. Tokunaga C, Yoshino K, Yonezawa K: mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 2004, 313:443-446.
19. Proud CG: mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 2004, 313:429-436.
20. Braun-Dullaeus RC, Mann MJ, Seay U, et al.: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001, 21:1152-1158.
21. Thomas G: The S6 kinase signaling pathway in the control of development and growth. Biol Res 2002, 35:305-313.
22. Hudson CC, Liu M, Chiang GG, et al.: Regulation of hypoxia-inducible factor 1 expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
23. Treins C, Giorgetti-Peraldi S, Murdaca J, et al.: Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002, 277:27975-27981.
24. Abraham RT: mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004, 279:299-319.
25. Arsham AM, Howell JJ, Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003, 278:29655-29660.
26. Guba M, von Breitenbuch P, Steinbauer M, et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
27. Bruns CJ, Koehl GE, Guba M, et al.: Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004, 10:2109-2119.
28. Choi JH, Bertram PJ, Drenan R, et al.: The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Rep 2002, 3:988-994.
29. Peng T, Golub TR, Sabatini DM: The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002, 22:5575-5584.
30. Oldham S, Hafen E: Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 2003, 13:79-85. This review summarizes current studies, primarily from Drosophila organisms, regarding the function of the insulin/IGF system in the control of growth.
31. Gingras AC, Raught B, Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol 2004, 279:169-197.
32. Nojima H, Tokunaga C, Eguchi S, et al.: The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003, 278:15461-15464.
33. Lekmine F, Uddin S, Sassano A, et al.: Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003, 278:27772-27780.
34. Hara K, Maruki Y, Long X, et al.: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
35. Abraham RT: Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 2002, 111:9-12.
36. Beugnet A, Wang X, Proud CG: Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem 2003, 278:40717-40722.
37. Gao X, Zhang Y, Arrazola P, et al.: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002, 4:699-704.
38. Tee AR, Fingar DC, Manning BD, et al.: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002, 99:13571-13576.
39. Potter CJ, Pedraza LJ, Xu T: Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002, 4:658-665.
40. Valentinis B, Baserga R: IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001, 54:133-137.
41. Thimmaiah KN, Easton J, Huang S, et al.: Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Res 2003, 63:364-374.
42. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963. Excellent review of the functions of the PTEN tumor suppressor pathway and related signaling elements, particularly with regard to tumorigenesis.
43. Jaeschke A, Hartkamp J, Saitoh M, et al.: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002, 159:217-224.
44. Kwiatkowski DJ: Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther 2003, 2:471-476.
45. Krymskaya VP: Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal 2003, 8:729-739.
46. Manning BD, Cantley LC: United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 2003, 31:573-578.
47. Inoki K, Li Y, Zhu T, et al.: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
48. Manning BD, Tee AR, Logsdon MN, et al.: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002, 10:151-162.
49. Neshat MS, Mellinghoff IK, Tran C, et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001, 98:10314-10319.
50. Choe G, Horvath S, Cloughesy TF, et al.: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003, 63:2742-2746.
51. Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998, 58:627-632.
52. Campbell RA, Bhat-Nakshatri P, Patel NM, et al.: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824.
53. th NCI-EORTC-AACR symposium on molecular targets and cancer therapeutics. Eur J Cancer 2002, S158.
54. Cui X, Zhang P, Deng W, et al.: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003, 17:575-588.
55. Liaw D, Marsh DJ, Li J, et al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
56. Li J, Yen C, Liaw D, et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
57. Duerr EM, Rollbrocker B, Hayashi Y, et al.: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16:2259-2264.
58. Liu W, James CD, Frederick L, et al.: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997, 57:5254-5257.
59. Mills GB, Lu Y, Fang X, et al.: The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001, 28(5 Suppl 16):125-141.
60. Perren A, Weng LP, Boag AH, et al.: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155:1253-1260.
61. Fry MJ: Phosphoinositide 3-kinase signaling in breast cancer: how big a role might it play? Breast Cancer Res 2001, 3:304-312.
62. DeGraffenried LA, Fulcher L, Hidalgo M: Reduced PTEN expression in breast cancer cells correlates with increased sensitivity to inhibitors of the PI3K pathway. Proc Am Assoc Cancer Res 2001, 42:128.
63. Podsypanina K, Lee RT, Politis C, et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci USA 2001, 98:10320-10325.
64. Shi Y, Gera J, Hu L, et al.: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002, 62:5027-5034.
65. Mills GB, Lu Y, Kohn EC: Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:10031-10033.
66. Eshleman JS, Carlson BL, Mladek AC, et al.: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002, 62:7291-7297.
67. Grunwald V, DeGraffenried L, Russel D, et al.: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
68. Huang S, Houghton PJ: Mechanisms of resistance to rapamycins. Drug Resist Updat 2001, 4:378-391.
69. Dilling MB, Germain GS, Dudkin L, et al.: 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002, 277:13907-13917.
70. Xu G, Zhang W, Bertram P, et al.: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004, 4:893-900.
71. Tee AR, Manning BD, Roux PP, et al.: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003, 13:1259-1268.
72. Huang S, Liu LN, Hosoi H, et al.: p53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res 2001, 61:3373-3381.
73. Huang S, Shu L, Dilling MB, et al.: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell 2003, 11:1491-1501.
74. Sausville EA, Zaharevitz D, Gussio R, et al.: Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther 1999, 82:285-292.
75. Hosoi H, Dilling MB, Liu LN, et al.: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998, 54:815-824.
76. Boffa DJ, Luan F, Thomas D, et al.: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004, 10:293-300.
77. Huang S, Bjornsti MA, Houghton PJ: Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003, 2:222-232.
78. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19:6680-6686.
79. Clarkson T, Metcaif CA III, Rozamus LW, et al.: Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc Am Assoc Cancer Res 2002, 43:95.
80. Raymond E, Alexandre J, Faivre S, et al.: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347. Describes the results of a phase I and pharmacokinetic evaluation of CCI-779 and reports antitumor activity in several tumor types and well-tolerated dose levels.
81. Hidalgo H, Rowinsky E, Erlichman C, et al.: CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc Am Soc Clin Oncol 2000, 19:187.
82. Forouzesh B, Buckner J, Adjei A, et al.: Phase I, bioavailabllity, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. Eur J Cancer 2002, 38(Suppl 7):S54.
83. Punt CJ, Boni J, Bruntsch U, et al.: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003, 14:931-937.
84. Atkins MB, Hidalgo M, Stadler WM, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918. Randomized phase 2 study in patients with advanced RCC demonstrated objective activity in high-risk patients and provided support for phase 3 studies.
85. Hidalgo M, Atkins MB, Stadler WM, et al.: A randomized double-blind phase 2 study of intravenous (IV) CCI-779 administered weekly to patients with advanced renal cell carcinoma (RCC): prognostic factor analysis. Proc Am Soc Clin 2003, 22:201.
86. Smith JW, Ko Y-J, Dutcher J, et al.: Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2004, 23:384.
87. Chan S, Scheulen ME, Johnston S, et al.: Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens. Proc Am Soc Clin Oncol 2004, 23:70. Preliminary report of a phase 2 study of CCI-779 in previously treated patients with advanced breast cancer. Demonstrated an intriguing, albeit moderate, level of anticancer activity in patients whose tumors were not screened for molecular aberrations associated with mTOR activation.
88. Baselga J, Fumoleau P, Gil M, et al.: Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol 2004, 23:544.
89. Witzig TE, Geyer SM, Salim M, et al.: A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: interim analysis of 18 patients. Blood 2003, 102:11.
90. Panwalkar A, Verstovsek S, Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100:657-666. Reviews the rationale for studies of rapamycin inhibition in patients with hematologic malignancies and summarizes early clinical trials of CCI-779 in these diseases.
91. Galanis E, Buckner JC, Maurer M, et al.: NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM), Proc Am Soc Clin Oncol 2004, 23:107.
92. Margolin KA, Longmate J, Baratta T, et al.: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Proc Am Soc Clin Oncol 2004, 23:712.
93. Boulay A, Zumstein-Mecker S, Stephan C, et al.: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64:252-261. These results demonstrate a correlation between the antitumor efficacy of intermittent RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs and suggest that long-term monitoring of PBMC-derived S6K1 activity levels could be used for assessing RAD001 treatment schedules in cancer patients.
94. O'Donnell A, Faivre S, Judson I, et al.: A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 2003, 22:200.
95. Lane H, Tanaka C, Kovarik J, et al.: Preclinical and clinical pharmacokinetic/pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD001, in oncology. Proc Am Soc Clin Oncol 2003, 22:237 (abstr 951).
96. Di Cosimo S, Matar P, Rojo F, et al.: Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). Proc Am Soc Clin Oncol 2004, 23:213.
97. Pacey S, Rea D, Steven N, et al.: Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. Proc Am Soc Clin Oncol 2004, 23:224.
98. Van Oosterom T, Dumez H, Desai J, et al.: Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Soc Clin Oncol 2004, 23:195.
99. Mita MM, Rowinsky EK, Goldston ML, et al.: Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily x 5 every other week in patients (pts) with refractory or advanced malignancies. Proc Am Soc Clin Oncol 2004, 23:214.
100. Desai AA, Janisch L, Berk LR, et al.: A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc Am Soc Clin Oncol 2004, 23:232.
101. Dudkin L, Dilling MB, Cheshire PJ, et al.: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001, 7:1758-1764.
102. Peralba JM, DeGraffenried L, Friedrichs W, et al.: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892. Results of studies of S6K1 assay in the PBMCs of patients participating in a multidose phase 2 study of CCI-779 in patients with RCC to determine its relation with dose and plasma concentration of the agent and its value as a predictor of treatment efficacy. Kinase inhibition did relate to TTP.
103. Rowinsky EK: Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies. Clin Cancer Res 2004, 10:4220s-4226s.
104. Noh WC, Mondesire WH, Peng J, et al.: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10:1013-1023. In addition to demonstrating prominent antitumor activity with rapamycin in breast cancer cell lines, this report showed that the ratio of total protein levels of 4E-BP1 to 4E did not predict sensitivity. By contrast, overexpression of S6K1, and phosphorylated Akt independent of PTEN status, and decreased cyclin D1 related to rapamycin sensitivity. Targeting S6K1 and Akt with small interfering RNA and dominant-negative constructs, respectively, decreased rapamycin sensitivity. Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as rapamycin-sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.
105. Gera JF, Mellinghoff IK, Shi Y, et al.: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004, 279:2737-2746.